L-carnitine supplementation for the treatment of chemoradiotherapy-induced fatigue in patients with head and neck cancer

L-carnitine supplementation for the treatment of chemoradiotherapy-induced fatigue in patients with head and neck cancer - L-carnitine supplementation for the treatment in patients with head and neck cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020482

Enrollment

Registered

2016-01-07

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

supplementation of L-carnitine, 7 weeks, 1 time/everyday, 1000mg control, nothing to treat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with head and neck cancer recieving CDDP-based chemoradiotherapy

Exclusion criteria

Exclusion criteria: severe liver disfunction sereve kidney disfunction Diabetic patient

Design outcomes

Primary

Measure	Time frame
to alleviate cancer-related fatigue in patients receiving chemoradiotherapy at the time after chemo-radiation therapy	—

Countries

Japan

Contacts

Public ContactKazuhira Endo

Kanazawa University Hospital Otolaryngology

endok@med.kanazawa-u.ac.jp81-76-265-2413

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026